EMERGENCY USE AUTHORIZATION (EUA) SUMMARY FOR THE EVERLYWELL COVID-19 & FLU TEST HOME COLLECTION KIT

For *In vitro* Diagnostic Use
Rx Only
For use under Emergency Use Authorization (EUA) only

Home collected anterior nasal swabs self-collected with the Everlywell COVID-19 & Flu Test Home Collection Kit will be sent to High Complexity Laboratories that have been designated by Everlywell, Inc. All laboratories will be certified under the Clinical Laboratory Improvement Amendments of 1988(CLIA), 42 U.S.C. §263a and meet the requirements to perform high complexity tests. Laboratories will run the specimens collected using the Everlywell COVID-19 & Flu Test Home Collection Kit on an in vitro diagnostic (IVD) molecular test that is indicated for use with the Everlywell COVID-19 & Flu Test Home Collection Kit per the Instructions for Use that was reviewed by the FDA under the test EUA.

INTENDED USE

The Everlywell COVID-19 & Flu Test Home Collection Kit is intended for the collection of anterior nasal swab specimens at home from individuals age 18 years and older (self-collected), 16 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance) when suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider. Clinical signs and symptoms of respiratory viral infection due to SARS-CoV-2 and influenza can be similar. Specimens collected using the Everlywell COVID-19 & Flu Test Home Collection Kit are transported at ambient temperature for testing at an authorized laboratory. Nucleic acids from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), influenza A virus, and/or influenza B virus are maintained in the specimen packaging and is only for use in molecular diagnostic testing performed using an in vitro diagnostic (IVD) test for the detection and differentiation of SARS-CoV-2, influenza A virus, and/or influenza B virus that is indicated for use with the Everlywell COVID-19 & Flu Test Home Collection Kit.

Testing is limited to laboratories designated by Everlywell, Inc. that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meet requirements to perform high complexity tests. Testing is also limited to molecular diagnostic tests that are indicated for use with the Everlywell COVID-19 & Flu Test Home Collection Kit.

The Everlywell COVID-19 & Flu Test Home Collection Kit is only for use under the Food and Drug Administration's Emergency Use Authorization.

DEVICE DESCRIPTION AND TEST PRINCIPLE

The Everlywell COVID-19 & Flu Test Home Collection Kit will only be dispensed to patients meeting the inclusion criteria based on the information provided through the Everlywell website COVID-19 & Flu questionnaire and reviewed by the Physician Wellness Network (PWN). The PWN will determine test eligibility and write prescriptions for testing. PWN will also follow up all positive test results by contacting the patients. Patients with inconclusive/invalid test results will also be contacted and notified of the test result. Negative patients will be notified by email and through the website portal.

The Everlywell COVID-19 & Flu Test Home Collection Kit is composed of sample registration instructions, sample collection instructions, sample preparation and shipping instructions, anterior nasal swab, saline in a tube, shipping materials, and return labels. Instructions are included in the kit to direct the home users on how to appropriately self-collect the anterior nasal swab specimen (18 years and older), self-collect under adult supervision (16 years and older) or how to appropriately collect the anterior nasal swab specimen from a child (for ages 2-15) and place it in the saline transport tube, how to properly package the specimen, and how to mail the specimen back to the laboratory using the pre-labeled return envelope. Each Everlywell COVID-19 & Flu Test Home Collection Kit is intended to be returned via overnight courier service at ambient conditions on the same day of sample collection in accordance with the standards as put forth by the CDC and WHO for the transport of suspected COVID-19 samples.

Specimens received at the clinical laboratory for testing will undergo review and accessioning prior to acceptance for testing.

Testing is limited to laboratories designated by Everlywell that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests and which run the specimens on an FDA authorized NAAT test that is indicated for use with the Everlywell COVID-19 & Flu Test Home Collection Kit per the Instructions For Use.

REAGENTS AND MATERIALS

The Everlywell COVID-19 & Flu Test Home Collection Kit includes the following:

POLY MAILER 7.5 X 10.5
2D BARCODE LABEL
KIT ID STICKERS
RETURN BOX

UN3373 LABEL (pre-applied to return materials)
MEDIUM ALCOHOL PREP PAD
ABSORBENT SHEET
SMALL BIOHAZARD BAG
INNER BOX TRAY 1-3
HELP AND CONTACT NUMBER
SHIPPING AND PREPARATION INSTRUCTIONS
SPECIMEN COLLECTION INSTRUCTIONS
WELCOME PANEL WITH KIT ID
WHITE TRAY
RETURN SHIPPING LABEL
ANTERIOR NASAL SWAB
TRANSPORT tube (0.9% Saline)

MEDICAL OVERSIGHT AND PROCESS TO BE USED:

Medical oversight of the Everlywell COVID-19 & Flu Test Home Collection Kit ordering process is provided by the third-party physician network, PWN Health (PWN). PWN is an independent company that employs or contracts with physicians licensed in all 50 states, healthcare professionals, and non-clinical patient care coordinators as support staff. Patient care coordinators are overseen by multiple layers of clinical and non-clinical professionals.

Individuals who are 18 years and older may request the Everlywell COVID-19 & Flu Test Home Collection Kit collection device through the Everlywell website, where they are required to complete a COVID-19 & Flu questionnaire. Individuals who are 18 years and older may also request the Everlywell COVID-19 & Flu Test Home Kit collection device for children (ages 2-17). PWN Health designed the health screening questions and implementation algorithm utilized at the point of customer purchase on the digital platform. The information collected in the questionnaire is provided to PWN for review.

Before the kit is shipped to the patient's home and before the self-collected sample can be processed at the CLIA lab, PWN generates the lab test requisition for the end-user, if appropriate, based on CDC-approved eligibility criteria. After the self-collected sample is

processed at the CLIA lab, PWN reviews and approves the test results, and recommends follow-up action and education to the end-user of the ***Everlywell COVID-19 & Flu Test Home Collection Kit***, as outlined below.

The PWN COVID-19 care program takes into consideration end-user symptoms and potential for exposure when determining the likelihood of respiratory viral infection consistent with COVID-19. In the event that an end-user is experiencing severe symptoms, an at-home test is not recommended and the end-user is advised to contact their healthcare provider for further actions and instructed to not delay medical attention.

The opportunity to contact a physician/healthcare provider is made available at all points in the process to ask questions and/or to receive other information/education. Additionally, physician or trained healthcare provider consultations are available to anyone who requests one regardless of test result.

The performance of the Everlywell COVID-19 & Flu Home Collection Kit was established using symptomatic individuals and performance may be different with asymptomatic individuals.

PATIENT INCLUSION/EXCLUSION CRITERIA

Inclusion of patients suspected of respiratory viral infection consistent with COVID-19 when home collection is determined to be appropriate by a healthcare provider.

INSPECTION OF SPECIMENS:

Applies to specimens received from patients using home collection kit.
Specimens received through the Everlywell Home Collection Kit should be checked for the following criteria before entering the workflow:

- **Improper return of sample packaging -** sample not returned in supplied packing materials; sample not returned in biohazard bag; sample not in correct collection/transport device or tube; insufficient volume/ or leak/dry tube
- **Not Registered** - customer did not register kit on EW platform
- **QNS** - customer did not provide enough specimen for processing
- **Missing Information** - customer did not write name, date of birth, or date of collection on the specimen
- **Incorrect Name** - name on the requisition does not match what is written on specimen
- **Invalid Date** - DOB on the requisition does not match what is written on the specimen or the date of collection that is written on specimen is either in the future or exceeded expiration
- **Other** - any other error that requires Everlywell review; these are typically rare events, often associated with other extenuating factors

- **Wrong Lab –** customer mixed up return shipping labels and specimen arrived at the incorrect lab for processing
- **Missing Barcode –** customer received replacement materials at home and forgot to write the Kit ID on the new specimen

CONTROLS TO BE USED WITH THE COVID-19 RT-PCR TEST

1) A negative (no template) control is needed to eliminate the possibility of sample contamination on the assay run and is used on every assay plate. This control is molecular grade, nuclease-free water.

2) A positive template control for each target is used to verify that the assay run is performing as intended and is used on every assay plate. The positive template controls do not include the RNase P target and will result as "undetermined" for that marker.

3) An internal control targeting RNase P is needed to verify that nucleic acid is present in every sample and is used for every sample processed. This also serves as the extraction control to ensure that samples resulting as negative contain nucleic acid for testing.

4) A negative extraction control (optional) is a previously characterized negative patient sample. It serves both as a negative extraction control to monitor for any cross-contamination that occurs during the extraction process, as well as an extraction control to validate extraction reagents and successful RNA extraction.

INTERPRETATION OF RESULTS

Test results are transmitted by the laboratory to PWN for review, interpretation and reporting. Following the PWN review, PWN releases those results to the end user of the Everlywell COVID-19 & Flu Test Home Collection Kit.

All test controls should be examined prior to interpretation of patient results. If the controls are not valid, the patient results cannot be interpreted. PWN's protocol provides for real-time communication throughout the testing process, including when the individual is waiting for the test kit, while the individual is waiting for results, and after the result is provided. Educational materials include information on maintaining social distancing or isolation, monitoring for severe symptoms, and seeking care when necessary and adheres to both CDC and HHS guidelines. Patient care coordinators, other healthcare professionals, and physicians are available at all times throughout this process for questions/concerns.

In general, SARS-CoV-2, Influenza A and Influenza B test results are divided into "Positive" (positive/detected), "Negative" (negative/not detected), and "Invalid" (no result, indeterminate).

PWN makes phone calls and outreach attempts as soon as possible after the result is reported in order to speak to the individual and provide education and additional information. In the case of positive results:

- Individuals will receive a result reporting call and a letter in the case that they cannot be reached
- Call and outreach attempts will be made promptly from the time of receiving the test results
- Outreach calls provide result of the test, counseling on the disease and next steps based on immediate symptoms including isolation vs in-person or emergency care, and the opportunity to have a telehealth consult with a physician or trained healthcare provider licensed in the state of where the individual is located
- Results are reported by PWN to public health agencies as required

Patients with inconclusive/invalid results will also be contacted and notified of the results. Additionally, physician or trained healthcare provider consultations are available to anyone who requests one regardless of test result. All individuals have the opportunity to follow up with the physician or trained healthcare provider with regards to what to watch for, specific symptoms, self- quarantine questions as appropriate, and when to seek care with necessary parameters provided.

PERFORMANCE EVALUATION

1) Everlywell COVID-19 & Flu Test Home Collection Kit Sample Stability Studies:

The stability study described below was conducted by Exact Sciences Laboratories. Exact Sciences Laboratories has granted a right of reference to Everlywell in support of their EUA request.

A sample stability study was performed to verify stability of nasal swab specimens collected at home and shipped to Exact Sciences Laboratories. This study pertains to the stability of residual clinical nasal specimens in 0.9% saline and positive for influenza A, influenza B or SARS-CoV-2.

Samples were prepared using pooled negative clinical nasal matrix from residual samples and live viral stocks of influenza A or influenza B, or a heat-inactivated stock of SARS-CoV-2 at 2X (weak positive) or 7.5X (moderate positive) LoD. To prepare each sample, spiked clinical nasal matrix was loaded onto a swab, and the swab was eluted in 0.9% saline. Negative clinical samples consisting of only pooled negative clinical nasal matrix in 0.9% saline were also included in the study. Samples were evaluated to simulate winter and summer conditions following the shipping condition recommendations outlined in the ISTA7D 2007. For comparison, the control condition consisted of 2x LoD, 7.5x LoD, and negative samples at 2 to 8 ºC.

After the temperature challenges were completed, samples were tested with the Exact Sciences COVID-Flu Multiplex Assay. Acceptance criteria was defined as ≥ 95% agreement or greater for positive and negative samples, and the mean Ct of samples tested after each of the storage conditions is not greater than 3 Ct compared to the control condition. No shifts in the mean Ct for the test condition compared to the mean control condition Ct were greater than 3 Ct, **Table 1**. All test conditions met the acceptance criteria and supported the stability of influenza A, influenza B, and SARS-CoV-2 specimens through winter and summer shipping conditions up to 72 hours.

Table 1: Specimen Stability Average Ct Result Summary

Condition	Replicates (per condition)	Sample Type	SARS-CoV-2 Ct	Flu A Ct	Flu B Ct	RP Ct
Control Condition	20	Weak Positive SARS-Cov-2 (CV)	33.38	NA	NA	30.52
Sumer Profile			33.54	NA	NA	30.34
Winter Profile			33.60	NA	NA	30.23
Control Condition	10	Moderate Positive SARS-Cov-2 (CV)	32.46	NA	NA	30.20
Sumer Profile			32.27	NA	NA	30.21
Winter Profile			32.46	NA	NA	30.08
Control Condition	20	Weak Positive Flu A	NA	31.88	NA	30.11
Sumer Profile			NA	32.13	NA	29.90
Winter Profile			NA	32.40	NA	30.10
Control Condition	10	Moderate Positive Flu A	NA	30.59	NA	30.24
Sumer Profile			NA	31.03	NA	29.86
Winter Profile			NA	31.70	NA	30.21
Control Condition	20	Weak Positive Flu B	NA	NA	31.80	29.81
Sumer Profile			NA	NA	31.80	29.48
Winter Profile			NA	NA	32.86	29.59
Control Condition	10	Moderate Positive Flu B	NA	NA	30.84	29.94
Sumer Profile			NA	NA	30.99	29.48
Winter Profile			NA	NA	31.97	29.88
Control Condition	10	Negative	NA	NA	NA	30.42
Sumer Profile			NA	NA	NA	30.06
Winter Profile			NA	NA	NA	29.95

2) Everlywell COVID-19& Flu Test Home Collection Kit Human Usability Studies:

Usability study for adults age 18 and older

For every new test Everlywell launches, pre-release usability testing is conducted where comprehension of the collection experience including online and written instructions is

confirmed. In the course of product development, Everlywell conducts ongoing user research. This involves proactive in-depth interviews of customers who have recently completed a test to discuss their experience in an attempt to discover potential improvements. This information is reviewed and used to inform areas where users are confused by language and graphics, and those areas are changed to become more understandable.

Everlywell closely monitors user error rates and sample receipt/accessioning issues for all tests using standardized procedures.

At launch of the previously authorized Everlywell COVID-19 Test Home Collection Kit intended for at-home self-collection of anterior nasal swab specimens eluted in saline to detect SARS-CoV-2 virus only, Everlywell monitored the user error rate and implemented a usability assessment to identify and characterize user success with at-home collection of samples. Data tabulated from use of the kit from May 2020 through December 2020 are shown in the following table. The data are applicable to the Everlywell COVID-19 & Flu Test Home Collection Kit intended for at-home self-collection of anterior nasal swab specimens eluted in saline to detect SARS-CoV-2, influenza A and influenza B, as the kit components and self-collection instructions used for are highly similar.

	Total Count	**% of Total**
No. of kits returned to lab for processing	**201,290**	
Total samples identified with no errors	186,832	92.82%
Total samples identified with errors	14,457	7.18%
Errors resolved	13,668	94.54%
Total samples with no errors or resolved errors	**200,500**	**99.60%**
Unresolved error rate	**790**	**0.40%**
Description of Errors		
Not registered	4,314	2.14%
Rejected - Missing Identifiers	276	0.14%
Other	353	0.18%
Improper return of sample packing	4,086	2.03%
Incorrect Name	447	0.22%
Registered - Missing PWN Order	167	0.08%
Wrong Lab	1	0.00%
Invalid Date	1,227	0.61%
Missing Info	2,474	1.23%
Expired Order	169	0.08%
QNS	6	0.003%

In addition, over 19,000 collection kit users completed a survey addressing their experience with the Everlywell COVID-19 Test Home Collection Kit, including questions related to registration, specimen handling and collection, and kit return. Based upon the usability data and user feedback, the Instructions for Use have been refined since initial kit introduction.

Usability study for minors age 2-17

In addition, Everlywell conducted usability testing to assess self-collection involving minors aged 16 and 17 and parent-assisted collection of specimens from individuals 2-15 years of age. The study was conducted to evaluate the ability of individuals of various ages, ethnicities, and education levels to successfully perform home specimen collection. Parents and child participants completed a set of tasks related to various stages of using the kit to collect and return a sample from a minor in/from an at-home environment. Tasks covered the typical end-to-end process following receipt of the kit including online registration, sample collection, and return preparation and shipment to the laboratory. Participants recorded the process using their mobile device or computer camera. Participants received standard instructions provided in the kit and available on the Everlywell commercial site to complete specimen collection and shipping to the laboratory, and no additional interaction or direction from those conducting the study, apart from training related to informed consent, general study steps, and use of video recording occurred. Objective measures for the study included determination of the proportion of successful scenario completions (i.e. registered kits which ultimately yield valid results) and Ct values for internal sample controls targeting RNase P mRNA. Additionally, observed error types and rates were described. Post-use interviews/email outreach to further assess ease of kit use and instructions was obtained as well.

Evaluated samples from all but one participant tested positive for RNase P (93 of 94), indicating the presence of human nucleic acid. A number of the kits returned from the usability study experienced registration errors or were noted to have expired upon receipt to the laboratory. Based on the historical data above, however, these errors are considered to be an artifact of the usability study and are not expected to occur with regularity. For the critical collection, packaging, and shipping steps that were observed in the usability study, results were deemed acceptable for participating adults and minor children aged 2-17 years old. Results tallied from the optional survey conducted after kit use indicated no adverse results were reported and generally indicated success/ease of the collection process. Everlywell will continue to monitor usability of the kit and introduce improvements to the process as warranted. Based on the overall assessment of the usability study and in an effort to align with other home collection kits authorized for specimen collection from minors, the following changes were implemented in the Instructions for Use:

1. Added text to further clarify appropriate distance swab should be inserted during collection and collection method

2. Edited age limit warning/comments to facilitate collection, packaging, and shipment of specimens from minors 2-17 years of age.

WARNINGS:

- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA.
- This product has been authorized only for the home collection and maintenance of anterior nasal swab specimens as an aid in detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and/or influenza B, not for any other viruses or pathogens.
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of medical devices under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
- While it has been determined, based on reviewing studies evaluating specimen adequacy (e.g., by evaluating RNase P), that unobserved self-collected anterior nasal swab samples using the Exact Sciences Nasal Swab Home Collection Kit will likely contain similar levels of human cellular genetic material as HCP-collected anterior nasal swab samples, performance of testing self-collected anterior nasal swab samples using the Exact Sciences Nasal Swab Home Collection Kit has not been specifically evaluated.